Volume dodolan mangsa ngarep perusahaan: Exact Sciences Inc. (EXAS)

Exact Sciences growth is based on partnerships with oncology centers to implement Cologuard screening. Projected sales volume dynamics confirm this trajectory, where 3.25 serves as the current metric level. Stability is ensured by top-tier geneticists and robust patent protection, bolstered by the integration of tests into the Medicare system, which limits market entry for new players.

EXAS - Prakiraan volume dodolan Exact Sciences Inc. ing rentang 04.07.2022 - 04.04.2026

Rincian metrik komprehensif lan analitis Exact Sciences Corp (EXAS)

- kuotasi lan prakiraan analis:

Rega saham Exact Sciences|EXAS - Rata-rata rega prakiraan

- indikator kapitalisasi bursa perusahaan:

Biji pasar Exact Sciences Corp|EXAS - Nilai Bisnis

- statistik nilai buku emiten:

Nilai Buku saben Saham Exact Sciences|EXAS - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku exactsciences.com|EXAS - Gunggung Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Rasio Total Utang marang Ekuitas Exact Sciences|EXAS - Rasio silihan jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Cologuard|EXAS - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Exact Sciences Corp|EXAS - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Exact Sciences|Rasio cepet exactsciences.com

- statistik bathi lan rasio pasar:

EXAS - Asil keuangan resik|Proyeksi bathi mangsa ngarep Exact Sciences|EXAS - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Exact Sciences Corporation|EXAS - Rasio P/E diaturake wutah|Pangali EV/EBITDA Exact Sciences Corp|EXAS - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Exact Sciences|EXAS - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan exactsciences.com|EXAS - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Exact Sciences

- indikator volume dodolan lan pendapatan:

EXAS - Total pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan Exact Sciences|EXAS - Rasio kapitalisasi marang pendapatan|Multiplikator Forward P/S Exact Sciences Corp

Pambiji fundamental:EXAS Exact Sciences

Amid intense competition in the US market, Exact Sciences (EXAS) is scaling its early cancer detection platforms, which necessitates precise monitoring of commercial potential. This metric measures projected revenue on a daily basis, allowing investors to distinguish systemic decline from temporary asset undervaluation by assessing the balance of reliability and return through the company's planned sales dynamics.

Pesaing utama